Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

Verona Pharma plc (VRNA)

Pharmaceutical Preparations

https://www.veronapharma.com

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.

3 MORE LONDON RIVERSIDE
LONDON, X0

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/27/2017

Market Cap

2,207,451,215

Shares Outstanding

639,520,000

Weighted SO

79,940,007

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

VTYX --.--%

IDYA --.--%

PTGX --.--%

SNDX --.--%

DAWN --.--%

XFOR --.--%

INZY --.--%

ABOS --.--%

MREO --.--%

Beta

0.4370

Last Div

0.0000

Range

11.39-28.83

Chg

-0.0250

Avg Vol

1490885

Mkt Cap

2207451215

Exch

NASDAQ

Country

GB

Phone

44 20 3283 4200

DCF Diff

23.6637

DCF

3.5883

Div Yield

0.0000

P/S

2348.2125

EV Multiple

-15.6781

P/FV

13.1094

Div Yield %

0.0000

P/E

-17.5584

PEG

-0.5217

Payout

0.0000

Current Ratio

8.6107

Quick Ratio

8.6107

Cash Ratio

8.3688

DSO

1430.4041

DIO

0.0004

Op Cycle

1430.4046

DPO

1689.3849

CCC

-258.9804

Gross Margin

0.0457

Op Margin

-137.9421

Pretax Margin

-134.4090

Net Margin

-133.6469

Eff Tax Rate

0.0064

ROA

-0.2894

ROE

-0.5546

ROCE

-0.3361

NI/EBT

0.9943

EBT/EBIT

0.9744

EBIT/Rev

-137.9421

Debt Ratio

0.5000

D/E

1.2899

LT Debt/Cap

0.5621

Total Debt/Cap

0.5633

Int Coverage

-2298.3973

CF/Debt

-0.2482

Equity Multi

2.5799

Rec Turnover

0.2552

Pay Turnover

0.2161

Inv Turnover

897060.0000

FA Turnover

0.4112

Asset Turnover

0.0022

OCF/Share

-0.6648

FCF/Share

-0.6654

Cash/Share

4.9934

OCF/Sales

-57.3045

FCF/OCF

1.0008

CF Coverage

-0.2482

ST Coverage

-52.2497

CapEx Coverage

-1196.7528

Div&CapEx Cov

-1196.7528

P/BV

13.1094

P/B

13.1094

P/S

2348.2125

P/E

-17.5584

P/FCF

-40.9436

P/OCF

-40.9502

P/CF

-40.9502

PEG

-0.5217

P/S

2348.2125

EV Multiple

-15.6781

P/FV

13.1094

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 30, 06:00 Verona Pharma to Present at 44th Annual Canaccord Growth Conference The Motley Fool Dec 30, 06:50 3 Stocks That Could Be Monster Winners in 2024 The Motley Fool Dec 30, 06:50 3 Stocks That Could Be Monster Winners in 2024 Benzinga Dec 29, 13:24 Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves Benzinga Dec 29, 13:24 Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves Zacks Investment Research Dec 26, 08:45 Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day Seeking Alpha Nov 18, 02:54 Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment

Revenue Product Segmentation